Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Prof Hashim Ahmed
hashim.ahmed@imperial.ac.uk


Miss Increase Akinyemi
i.akinyemi@imperial.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Approaches to long-term active surveillance of patients with prostate cancer (IP9 – ATLAS)
Back

Approaches to long-term active surveillance of patients with prostate cancer (IP9 – ATLAS)

Recruiting

Open to: Male

Age: Mixed

London Dartford London Swansea London Southampton Rhyl Milton Keynes Watford Camberley Maldon Newcastle upon Tyne

Medical Conditions

Prostate cancer

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.



Background and study aims
The aim of this study for patients on active surveillance for prostate cancer is to demonstrate that the use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE-defined strategy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

01 Jul 2024 30 Jun 2027

Publications

2026 Protocol article in https://pubmed.ncbi.nlm.nih.gov/41990428/ (added 20/04/2026)

Patients will be randomly allocated to either MRI scans or the current NICE-defined standard.
Current (NICE-defined active surveillance): PSA test 3 monthly in year 1 and then 6 monthly with rectal exam annually. MRI will be carried out at 12 months (if not had one at diagnosis). A biopsy will be required if indicated due to changes in rectal exam or PSA.
Planned (regular MRI-based active surveillance): Patients with a visible lesion or medium-risk cancer will have PSA 6 monthly and MRI annually. All other patients will undergo PSA 6 monthly and MRI in years 1, 3 and 5.
For all patients, a targeted biopsy will be carried out if the MRI PRECISE score is >/=4.


Patients aged 18 years or above with a diagnosis of localised prostate cancer in the 9 months before the screening visit and who have chosen active surveillance

You can take part if:



You may not be able to take part if:


1. On active surveillance for greater than 9 months prior to the screening date2. Contraindication to MRI or gadolinium contrast3. Previous hip replacement to both hips4. Contraindication to performing a biopsy guided by a transrectal ultrasound probe


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Kings College Hospital
    Mapother House De Crespigny Park Denmark Hill
    London
    SE5 8AB
  • Darent Valley Hospital
    Darenth Wood Road
    Dartford
    DA2 8DA
  • Charing Cross Hospital
    Fulham Palace Road
    London
    W6 8RF
  • Morriston Hospital
    Heol Maes Eglwys Cwmrhydyceirw
    Swansea
    SA6 6NL
  • Chelsea & Westminster Hospital
    369 Fulham Road
    London
    SW10 9NH
  • Southampton
    Southampton General Hospital Tremona Road
    Southampton
    SO16 6YD
  • Ysbyty Glan Clwyd
    Glan Clwyd Hospital Rhuddlan Road Bodelwyddan
    Rhyl
    LL18 5UJ
  • Milton Keynes General Hospital
    Milton Keynes Hospital Standing Way Eaglestone
    Milton Keynes
    MK6 5LD
  • Watford General Hospital
    60 Vicarage Road
    Watford
    WD18 0HB
  • Frimley Park Hospital
    Portsmouth Road Frimley
    Camberley
    GU16 7UJ
  • St Peters Hospital
    Spital Road
    Maldon
    CM9 6EG
  • Freeman Hospital
    Freeman Hospital Freeman Road High Heaton
    Newcastle upon Tyne
    NE7 7DN

Participants will continue on their standard care pathway with monitoring, so will not be at risk of progression not being detected. Those patients in the intervention group will have additional MRI scans. These will be non-contrast so there is no risk from having repeated 1-2 yearly injections of gadolinium contrast. Patients with contraindications to MRI will not be taking part in the study so will not be exposed to an unnecessary MRI.

Miss Increase Akinyemi
i.akinyemi@imperial.ac.uk


Prof Hashim Ahmed
hashim.ahmed@imperial.ac.uk



The study is sponsored by Imperial College London and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); Grant Codes: NIHR152027.




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: ISRCTN11447662

Or CPMS: 59385

Last updated 20 April 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top